Atezolizumab, an anti-PD-L1 antibody, has been shown to provide clinically relevant improvement of overall survival (OS) versus docetaxel in patients with previously treated metastatic NSCLC, regardless of PD-L1 expression 12. The gene discussed is CD274; the disease is non-small cell lung carcinoma.